

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>			<b>Complete if Known</b>		
			Application Number	09/435,992	
			Filing Date	November 8, 1999	
			First Named Inventor	Hanna, et al.	
			Art Unit	1644	
			Examiner Name	P. Gambel <i>5</i>	
			Attorney Docket Number	3037003-0276478(1999-30-0466A)	
Sheet	1	of	2		

[illegible][illegible]

Examiner Signature	GAMBA 6/27/03	Date Considered	
-----------------------	---------------	--------------------	--


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

English language translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Control number: Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
<b>Application Number</b>				09/435,992	
<b>Filing Date</b>				November 8, 1999	
<b>First Named Inventor</b>				Hanna, et al.	
<b>Group Art Unit</b>				1644	
<b>Examiner Name</b>				P. Gambel	
<b>Attorney Docket Number</b>				037003-0275478 (1999-30-0466A)	
Sheet	2	of	2		

[illegible]


Examiner Signature	Ganga 6/28/03	Date Considered	
-----------------------	---------------	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

FORM PTO-1449 (modified)  
To: U.S. Department of Commerce  
(PW FORM PAT-1449)  
Patent and Trademark Office



Atty.  
Dkt. No.

Client Ref.

037003-0275478

1999-30-0456

**INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT**

Applicant: Hanna, et al.

Appln. No.: 09/435,992

Filing Date: November 8, 1999

Examiner: P. Gambel

Group Art Unit: 1644

Date: April 14, 2003

Page 1 of 2

**U.S. PATENT DOCUMENTS**

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
RG	AR 601,138	03/1898	Hall			
	BR 5,736,137	04/1998	Anderson, et al.	424	133.1	
	CR 5,916,560	06/1999	Larsen, et al.	424	154.1	
	DR 6,001,358	12/1999	Black, et al.	424	154.1	
	ER					

**FOREIGN PATENT DOCUMENTS**

	Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract		Translation Readily Available	
					Enclosed	No	Enclose	No
^	FR WO 98/19706	05/1998	PCT	Anderson, et al.				
v	GR WO 98/39026	09/1998	PCT	Kalled, et al.				
:	HR WO 98/56417	12/1998	PCT	Harlan, et al.				
3	IR WO 00/44788	08/2000	PCT	Braslawsky, et al.				
~	JR WO 01/34194 A1	05/2001	PCT	Hanna, et al.				
\	KR WO 01/89567 A1	11/2001	PCT	Anderson, et al.				
4	LR WO 02/04021 A1	01/2002	PCT	Hanna, et al.				

**OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)**

MR	Akpek G., et al., Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma, Cancer, 86(7):1368-1376 (Oct. 1, 1999) [XP-002906151]				
NR	Benoit, N., et al., Increased inhibition of proliferation of human B cell lymphomas following ligation of CD40, and either CD19, CD20, CD95 or surface immunoglobulin, Immunopharmacology 35:129-139 (1996) [XP-002213373]				
OR	Buske, C., et al. Monoclonal antibody therapy for B cell Non-Hodgkin's lymphomas: Emerging concepts of a tumour-targeted strategy, European Journal of Cancer, 35(4):549-557 (1999) [XP-001010018]				
PR	Dallaire, B., et al., New aspects of treatment of B-cell non-Hodgkin's lymphomas with monoclonal antibodies. IDEC-C2B8 (Rituximab): Biology and preclinical studies, Journal of Molecular Medicine, Springer Verlag, DE, 75(7):B230-B231 (1997) [XP-000952701]				
QR	Davis, J., et al., Results of a phase I, single-dose, dose-escalating trial of a humanized anti-CD40L monoclonal antibody (IDEC 131) in patients with systemic lupus erythematosus (SLE), Arthritis and Rheumatism, Lippincott, Philadelphia, US, 42(9):S281 (September 1999) [XP-002161703]				
RR	Furman, R., et al., Modulation of NF- $\kappa$ B activity and apoptosis in chronic lymphocytic leukemia B cells, The Journal of Immunology, 164(4):2200-2206 (February 15, 2000) [XP-002203960]				
SR	Gelber, E., et al., Effect of immunosuppressive agents on the immunogenicity and efficacy of an immunotoxin in mice, Clinical Cancer Research, 4(5):1297-1304 (May 1998) [XP-002161701]				

Gambel 6/27/03

#31

OIP  
APR 1 6 2003  
PATENT & TRADEMARK

TECH CENTER 1600/2900  
APR 2 1 2003  
RECEIVED

TR	Ghetie, M., et al., Anti-CD19 inhibits the growth of human B-cell tumor lines in vitro and of Daudi cells in SCID mice by inducing cell cycle arrest, Blood, 83(5):1329-1336 (March 1, 1994) [XP-002088438]			
VR	Gottlieb, A., et al., Results of a single-dose, dose-escalating trial of an anti-B7.1 monoclonal antibody (IDEC-114) in patients with psoriasis, Journal of Investigative Dermatology, 114(4):840 (April 2000) [XP-002203912]			
VR	Green, K., et al., Evidence for a continued requirement of rCD40/CD40 ligand (CD154) interactions in the progression of LP-BM5 retrovirus-induced murine aids, Virology, 241(2):260-268 (February 15, 1998) [XP-002161702]			
WR	Hariharan, K., et al., Therapeutic activity of IDEC-114 (Anti-CD80) and Rituximab (Rituxan®) in B-cell lymphoma, Blood, 98(11, part 1):608a (November 16, 2001) [XP-001079527]			
XR	Heath, A., et al., Antibodies to murine CD40 stimulate normal B lymphocytes but inhibit proliferation of B lymphoma cells, Cellular Immunology, 152:468-480 (1993) [XP-002110518]			
YR	Juwied, M., et al., Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody, Cancer Research (Suppl.), 55:5899s-5907s (December 1, 1995) [XP-002070325]			
ZR	LaPlante, S., et al., Cost-efficacy evaluation of fludarabine phosphate in the treatment of chronic lymphocytic leukemia refractory to other therapies, European Journal of Cancer, Pergamon Press, Oxford, GB, 33:S29-30 (November 1997) [XP-004284486]			
AAR	Levy, R., 1999 keystone symposium on B lymphocyte biology and disease: B cell malignancy II session, Biochimica Et Biophysica Acta, 1424(2-3):R43-4 (October 29, 1999) [XP-000982627]			
BBR	O'Brien S., et al., Phase I/II study of Rituxan in chronic lymphocytic leukemia (CLL), Blood, 92(10 supp. 01, prt 1/2):105A (November 15, 1998) [XP-001062170]			
CCR	Ouaaz, F., et al., Growth arrest and terminal differentiation of leukemic myelomonocytic cells induced through ligation of surface CD23 antigen, Blood, 84(9):3095-3104 (November 1994) [XP-001079834]			
DDR	Pathan, N., et al., Induction of apoptosis by IDEC-152 (Anti-CD23) in lymphoma cells, Blood, 98(11, part 1):367a (November 16, 2001) [XP-001079733]			
EER	Press, O., et al., Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody, Journal of Clinical Oncology, 7(8):1027-1038 (August 1989) [XP-002936241]			
FFR	Romano, M., et al., Triggering of CD40 antigen inhibits fludarabine-induced apoptosis in B chronic lymphocytic leukemia cells, Blood, 92(3):990-995 (August 1, 1998)			
GGR	Tutt, A., et al., Monoclonal antibody therapy of B cell lymphoma: signaling activity on tumor cells appears more important than recruitment of effectors, The Journal of Immunology 161(6):3176-3185 (September 15, 1998) [XP-002213374]			
HHR	Silber, R., et al. Chemosensitivity of lymphocytes from patients with B-cell chronic lymphocytic leukemia to chlorambucil, fludarabine, and camptothecin analogs, Blood, 84(10):3440-3446 (November 15, 1994)			
IIR	Wrone-Smith T., Inhibition of costimulatory molecules as a means of treating a murine CD4+ T-cell dependent B-cell lymphoma, Database Cancerlit 'Online! (retrieved from STN Database accession no. 96606486) [XP-002203913] abstract and Dissertation Abstracts Int. 'BI, 56(2):736 (1995) ISSN: 0419-4217			

Examiner GAMBL G/2003 Date Considered: \_\_\_\_\_

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.